medRxiv
February 7, 2025
Andrew G. Breithaupt, Georges Naasan, Suzanne M. Shdo et al.
preprint
Abstract Psychosis is a common symptom in neurodegenerative diseases that contributes to significant patient and caregiver burden. While neuroimaging studies have implicated various brain regions in psychosis, findings have been inconsistent across different disease entities and psychosis subtypes. This study aimed to identify structural neuroanatomic changes associated with specific patterns...
medRxiv
January 5, 2025
Vinitha Ganesan, Lauren A. Fowler, Sahil Bajaj et al.
1 citation
preprint
Abstract Effective interventions are needed to address increasing mental health challenges that affect wellbeing. Sudarshan Kriya Yoga (SKY), a breath-based meditation, has previously shown to improve mental health. We conducted a pilot randomized controlled trial (RCT) in healthy individuals, to evaluate the feasibility of SKY intervention with an eight-week followup for studying its immediate...
medRxiv
2025
Benjamin R. Lewis, John Hendrick, Kevin Byrne et al.
3 citations
preprint
Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and...
medRxiv
December 27, 2024
preprint
A Virtual Music Mindfulness Tool for Individuals of African descent during COVID-19
medRxiv
October 13, 2024
Brian S. Barnett
preprint
Abstract This study surveyed researchers to assess the contents and funding success of federal grant applications for research into therapeutic applications of psychedelics in the United States. The author emailed an anonymous survey to the corresponding authors of the 50 most-cited articles on psychedelics published after 2000 and disseminated it via Twitter. Ten researchers responded,...
medRxiv
September 11, 2024
Marek Nikolič, Pedro A. M. Mediano, Tom Froese et al.
6 citations
preprint
Abstract Psilocybin is a classic psychedelic and a novel treatment for mood disorders. Psilocybin induces dose-dependent transient (4-6 hours) usually pleasant changes in perception, cognition, and emotion by non-selectively agonizing the 5-HT 2A receptors and negatively regulating serotonin reuptake, and long-term positive antidepressant effect on mood and well-being. Long-term effects are...
medRxiv
September 6, 2024
Hendrik-Jan De Vuyst, Angeliki-Ιlektra Karaiskou, Javier R. Soriano et al.
preprint
Abstract Objectives Neurofeedback training involves real-time monitoring and self-regulation of neural activity. Neurofeedback training paradigms have been widely employed in the context of meditation. Interestingly, prior research revealed focused attention meditation to be associated with desynchronized, non-harmonic, cross-frequency relationships between alpha and theta rhythms, suggesting...
medRxiv
July 12, 2024
Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto et al.
1 citation
preprint
Abstract Background Current drug policy classifies psilocybin, a substance produced by psychoactive mushrooms, as having a high potential for abuse, neglecting its therapeutic properties. We aimed to investigate if psilocybin mushrooms pose a risk to Brazilian public health compared to other toxic agents and whether evidence-based regulatory discussions are needed. Methods A retrospective...
medRxiv
June 20, 2024
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
preprint
Abstract Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders. Aims Assess hallucinogens’ efficacy for managing depressive and anxiety symptoms and evaluate their safety profiles. Method In five databases, we searched for randomized controlled trials of hallucinogens targeting depressive and anxiety symptoms....
medRxiv
June 17, 2024
preprint
Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression: A protocol for a systematic review and meta-analysis
medRxiv
January 4, 2024
Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al.
5 citations
preprint
Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...
medRxiv
July 8, 2023
Javier R. Soriano, Julio Rodriguez-Larios, Carolina Varon et al.
1 citation
preprint
ABSTRACT Objectives The study of neural and visceral oscillatory activities reveals that both subsystems and their interactions influence human cognition. In particular, cardiac and neural changes during self-regulation processes can be studied through a comparison of stress-inducing procedures and meditation practices. Methods In this study, we investigate the characteristic profiles of...
medRxiv
July 3, 2023
Drummond E-Wen Mcculloch, Anders S. Olsen, Brice Ozenne et al.
20 citations
preprint
A prominent theory of psychedelics is that they increase brain entropy. Twelve studies have evaluated psychedelic effects on fMRI brain entropy quantifications, no findings have been replicated. Here we evaluated these metrics in an independent 28-participant healthy cohort with 121 pre- and post-psilocybin fMRI scans. We assessed relations between brain entropy and plasma psilocin, brain...
medRxiv
June 1, 2023
Andreas Halman, Geraldine Kong, Jerome Sarris et al.
17 citations
preprint
Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes of using these substances are used in combination with other psychoactive drugs is limited. This systematic...
medRxiv
May 26, 2023
Tobias P. Whelan, Eileen Daly, Nicolaas A.j. Puts et al.
3 citations
preprint
Abstract Clinical trials of pharmacological approaches targeting the core features of autism have failed. This is despite evidence from preclinical studies, genetics, post-mortem studies and correlational analyses linking peripheral and central markers of multiple candidate neurochemical systems to brain function in autism. Whilst this has in part been explained by the heterogeneity of the...
medRxiv
May 10, 2023
Victoria di Virgilio, Amir Minerbi, Jagpaul Kaur Deol et al.
preprint
Abstract Background The World Health Organization (WHO) defines wellness as the optimal state of health of individuals and groups. No study to date has identified the impact of psychedelic medicines on optimizing wellness using a dimensional approach. Using this approach, treatment effects can be measured more broadly using a composite score of participants’ global perceptions of change for...
medRxiv
April 19, 2023
Jennifer Bennett, Michael D. Blough, Ian Mitchell et al.
3 citations
preprint
Abstract This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin, are increasingly being recognized as a successful treatment option for many mental health concerns. In order to decrease the risks associated with its clinical use, more data is required regarding its physiological effects in healthy individuals....
medRxiv
February 15, 2023
Victoria di Virgilio, Amir Minerbi, Jenna Fletcher et al.
1 citation
preprint
Abstract Background The World Health Organization (WHO) defines wellness as the optimal state of health of individuals and groups. No study to date has identified the impact of psychedelic medicines for optimizing wellness using a dimensional approach. Treatment effects can be measured more broadly using a composite score of participants’ global perceptions of change for pain, function, and...
medRxiv
January 17, 2023
Ryan Yermus, Michael Verbora, Sidney H. Kennedy et al.
2 citations
preprint
Abstract IMPORTANCE Ketamine-Assisted Psychotherapy (KAP) is an emerging treatment option to alleviate treatment resistant affective disorders, but its long term effectiveness remains unclear. OBJECTIVE To examine the treatment effects of KAP on anxiety, depression, and post traumatic stress disorder (PTSD) at 1, 3, and 6 months post treatment. DESIGN, SETTING, AND PARTICIPANTS This...
medRxiv
January 6, 2023
preprint
Effects of a Brief Mindfulness-Based Intervention on Pavlovian-To-Instrumental Transfer in Alcohol Use Disorder
medRxiv
December 11, 2022
Hannah Hartland, Kimia Mahdavi, Luke A. Jelen et al.
22 citations
Background: Ketamine may be effective in treating symptoms of anxiety, but the time profile of ketamine’s anxiolytic effect is ill-defined. This systematic review and meta-analysis investigated the anxiolytic effect of ketamine at different time points across a range of clinical settings. Methods: Electronic databases were searched to capture randomised control trials measuring the anxiolytic...
medRxiv
November 1, 2022
Natasha L. Mason, Attila Szabo, Kim P. C. Kuypers et al.
6 citations
preprint
Abstract Patients characterized by stress-related disorders such as depression display elevated circulating concentrations of pro-inflammatory cytokines and a hyperactive HPA axis. Psychedelics are demonstrating promising results in treatment of such disorders, however the mechanisms of their therapeutic effects are still unknown. To date the evidence of acute and persisting effects of...
medRxiv
September 9, 2022
Devon Stoliker, Leonardo Novelli, Franz X. Vollenweider et al.
4 citations
preprint
Abstract Classic psychedelics alter sense of self and patterns of self-related thought. These changes are hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-controlled clinical trial of 24 healthy adults under 0.215mg/kg psilocybin, we...
medRxiv
August 28, 2022
Dr. Rakesh Sarwal, R. Dhamija, K. Jain et al.
preprint
Background The COVID-19 pandemic has brought unparalleled challenges for health systems worldwide, the impact of which has also been borne by the Healthcare Professionals (HCPs). Numerous studies have revealed the positive effects of Pranayama and Meditation on mental health. The effect of Pranayama in improving mental health of frontline HCP exposed to Covid-19 patients has not been studied....
medRxiv
July 10, 2022
M. Madsen, Anja Sofie Petersen, Dea Siggaard Stenbæk et al.
5 citations
preprint
Abstract Chronic cluster headache (CCH) is an excruciating disorder of unknown pathophysiology, but hypothalamic dysfunction has been implicated. CCH is difficult to treat but on a case-basis, the psychedelic compound psilocybin is said to have beneficial effects. In this first-ever clinical trial ( NCT04280055 ), we evaluate in a small open-label study of CCH patients the feasibility and...